ID: ALA3356599

Max Phase: Preclinical

Molecular Formula: C26H40N10O6S

Molecular Weight: 620.74

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)c1nccs1

Standard InChI:  InChI=1S/C26H40N10O6S/c1-14(2)9-18(22(40)34-17(5-4-6-31-26(27)28)21(39)25-30-7-8-43-25)35-23(41)19(10-16-11-29-13-32-16)36-24(42)20(12-37)33-15(3)38/h7-8,11,13-14,17-20,37H,4-6,9-10,12H2,1-3H3,(H,29,32)(H,33,38)(H,34,40)(H,35,41)(H,36,42)(H4,27,28,31)/t17-,18-,19-,20-/m0/s1

Standard InChI Key:  QCZLVVCFUACPGA-MUGJNUQGSA-N

Associated Targets(Human)

Hepatocyte growth factor activator 149 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matriptase 677 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serine protease hepsin 242 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 620.74Molecular Weight (Monoisotopic): 620.2853AlogP: -1.45#Rotatable Bonds: 18
Polar Surface Area: 257.17Molecular Species: BASEHBA: 10HBD: 9
#RO5 Violations: 2HBA (Lipinski): 16HBD (Lipinski): 10#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.33CX Basic pKa: 11.35CX LogP: -3.70CX LogD: -5.52
Aromatic Rings: 2Heavy Atoms: 43QED Weighted: 0.04Np Likeness Score: -0.05

References

1. Han Z, Harris PK, Jones DE, Chugani R, Kim T, Agarwal M, Shen W, Wildman SA, Janetka JW..  (2014)  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.,  (11): [PMID:25408834] [10.1021/ml500254r]

Source